Erratum: Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer (Journal of Clinical Oncology (2018) DOI:10.1200/JCO.2018.77.7672);Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Journal of Clinical Oncology

Volumn 36, Issue 23, 2018, Pages 2386-2394

  Pietanza, M Catherine ^a   Waqar, Saiama N ^c   Krug, Lee M ^a   Dowlati, Afshin ^d   Hann, Christine L ^e   Chiappori, Alberto ^g   Owonikoko, Taofeek K ^h   Woo, Kaitlin M ^b   Cardnell, Robert J ⁱ   Fujimoto, Junya ⁱ   Long, Lihong ⁱ   Diao, Lixia ⁱ   Wang, Jing ⁱ   Bensman, Yevgeniva ^b   Hurtado, Brenda ^b   de Groot, Patricia ⁱ   Sulman, Erik P ⁱ   Wistuba, Ignacio I ⁱ   Chen, Alice ^f   Fleisher, Martin ^b   Heymach, John V ⁱ   Kris, Mark G ^a   Rudin, Charles M ^a   Byers, Lauren Averett ⁱ   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PLACEBO; TEMOZOLOMIDE; VELIPARIB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; SLFN11 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CIRCULATING TUMOR CELL; CONSTIPATION; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DNA DAMAGE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION STUDY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMAGING; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BIOMARKERS, TUMOR; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NUCLEAR PROTEINS; PLACEBOS; POLY (ADP-RIBOSE) POLYMERASE-1; PROMOTER REGIONS, GENETIC; SMALL CELL LUNG CARCINOMA; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEINS;

EID: 85052011208     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2018.18.01142     Document Type: Erratum

References (48)

1. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658-667, 1999
2. O’Brien ME, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441-5447, 2006
3. Eckardt JR, von Pawel J, Pujol JL, et al: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086-2092, 2007
4. Eckardt J, Gralla R, Palmer MC, et al: Topotecan as second-line therapy in patients with small cell lung cancer: A phase II study. Ann Oncol 7:107, 1996 (abstr 513)
5. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997
6. Depierre A, Von Pawel J, Hans K, et al: Evaluation of topotecan (hycamtin) in relapsed small-cell lung cancer (SCLC): A multicenter phase II study. Lung Cancer 18:35, 1997, (abstr 126)
7. Byers LA, Wang J, Nilsson MB, et al: Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2:798-811, 2012
8. Toyooka S, Toyooka KO, Maruyama R, et al: DNA methylation profiles of lung tumors. Mol Cancer Ther 1:61-67, 2001
9. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399, 2002
10. Esteller M, Herman JG: Generating mutations but providing chemosensitivity: The role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23:1-8, 2004
11. Pietanza MC, Byers LA, Minna JD, et al: Small cell lung cancer: Will recent progress lead to improved outcomes? Clin Cancer Res 21:2244-2255, 2015
12. Pietanza MC, Kadota K, Huberman K, et al: Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 18:1138-1145, 2012
13. Kalemkerian GP, Loo BW, Akerley W, et al: NCCN clinical practice guidelines in oncology: Small cell lung cancer. https://www.nccn.org/professionals/physician_gls/default.aspx
14. Memisoglu A, Samson L: Base excision repair in yeast and mammals. Mutat Res 451:39-51, 2000
15. Schreiber V, Amé JC, Dollé P, et al: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277:23028-23036, 2002
16. Tentori L, Graziani G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52: 25-33, 2005
17. Palma JP, Wang YC, Rodriguez LE, et al: ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 15: 7277-7290, 2009
18. Lok BH, Gardner EE, Schneeberger VE, et al: PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 23:523-535, 2017
19. Cardnell RJ, Feng Y, Diao L, et al: Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 19:6322-6328, 2013
20. de Bono J, Ramanathan RK, Mina L, et al: Phase I, dose-escalation, two-part trial of the parp inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 7:620-629, 2017
21. Owonikoko TK, Dahlberg SE, Khan SA, et al: A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer 89:66-70, 2015
22. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
23. Isakoff S, Overmoyer B, Tung N, et al: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28, 2010 (15, suppl)
24. Zauderer MG, Drilon A, Kadota K, et al: Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 86:237-240, 2014
25. Allison Stewart C, Tong P, Cardnell RJ, et al: Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget 8:28575-28587, 2017
26. Murai J, Tang SW, Leo E, et al: SLFN11 blocks stressed replication forks independently of ATR. Mol Cell 69:371-384 e6, 2018
27. Zoppoli G, Regairaz M, Leo E, et al: Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci USA 109:15030-15035, 2012
28. Polley E, Kunkel M, Evans D, et al: Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. J Natl Cancer Inst 108:djw122, 2016
29. Murai J, Feng Y, Yu GK, et al: Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7:76534-76550, 2016
30. Hattermann K, Mehdorn HM, Mentlein R, et al: A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. Anal Biochem 377: 62-71, 2008
31. Esteller M, Toyota M, Sanchez-Cespedes M, et al: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368-2371, 2000
32. Esteller M, Hamilton SR, Burger PC, et al: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797, 1999
33. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004
34. Danila DC, Heller G, Gignac GA, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053-7058, 2007
35. Krebs MG, Sloane R, Priest L, et al: Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29:1556-1563, 2011
36. Mateo J, Carreira S, Sandhu S, et al: DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697-1708, 2015
37. Lara PN Jr, Moon J, Redman MW, et al: Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: A patient-level analysis of Southwest Oncology Group trials. J Thorac Oncol 10:110-115, 2015
38. Ardizzoni A, Tiseo M, Boni L: Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials. Eur J Cancer 50: 2211-2218, 2014
39. Owonikoko TK, Behera M, Chen Z, et al: A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 7:866-872, 2012
40. Gupta SK, Mladek AC, Carlson BL, et al: Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20:3730-3741, 2014
41. Smith MA, Reynolds CP, Kang MH, et al: Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21:819-832, 2015
42. Hopkins TA, Shi Y, Rodriguez LE, et al: Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 13:1465-1477, 2015
43. Shen Y, Aoyagi-Scharber M, Wang B: Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 353:446-457, 2015
44. Lord CJ, Ashworth A: PARP inhibitors: Synthetic lethality in the clinic. Science 355:1152-1158, 2017
45. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
46. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
47. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244-250, 2015
48. Gardner EE, Lok BH, Schneeberger VE, et al: Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell 31:286-299, 2017